Alligator Bioscience Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Alligator Bioscience wird ein Gewinn- und Umsatzwachstum von 48.1% bzw. 5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 65.4% pro Jahr wachsen soll.

Wichtige Informationen

48.1%

Wachstumsrate der Gewinne

65.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.2%
Wachstumsrate der Einnahmen	5.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Apr 11

Estimating The Intrinsic Value Of Alligator Bioscience AB (publ) (STO:ATORX)

Feb 17

Gewinn- und Umsatzwachstumsprognosen

OM:ATORX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	124	-69	-66	-64	2
12/31/2025	122	-90	-196	-93	2
12/31/2024	261	-6	-201	86	3
3/31/2024	56	-249	-225	-223	N/A
12/31/2023	59	-249	-192	-189	N/A
9/30/2023	68	-232	-185	-182	N/A
6/30/2023	53	-231	-177	-175	N/A
3/31/2023	40	-213	-178	-177	N/A
12/31/2022	36	-193	-173	-173	N/A
9/30/2022	21	-177	-159	-159	N/A
6/30/2022	20	-163	-149	-148	N/A
3/31/2022	18	-152	-139	-139	N/A
12/31/2021	13	-142	-127	-127	N/A
9/30/2021	8	-139	-125	-125	N/A
6/30/2021	5	-133	-128	-128	N/A
3/31/2021	6	-133	-127	-127	N/A
12/31/2020	6	-143	-141	-141	N/A
9/30/2020	5	-169	-161	-160	N/A
6/30/2020	9	-194	-187	-185	N/A
3/31/2020	4	-209	-199	-197	N/A
12/31/2019	4	-210	-183	-181	N/A
9/30/2019	30	-181	-174	-172	N/A
6/30/2019	26	-164	-156	-154	N/A
3/31/2019	26	-152	-144	-141	N/A
12/31/2018	27	-150	-112	-104	N/A
9/30/2018	53	-107	-112	-97	N/A
6/30/2018	54	-93	-97	-80	N/A
3/31/2018	55	-86	-89	-71	N/A
12/31/2017	57	-64	N/A	-100	N/A
9/30/2017	12	-96	N/A	-80	N/A
6/30/2017	15	-77	N/A	-76	N/A
3/31/2017	18	-91	N/A	-41	N/A
12/31/2016	59	-48	N/A	-38	N/A
9/30/2016	55	-68	N/A	-52	N/A
12/31/2015	292	207	N/A	205	N/A
12/31/2014	1	-77	N/A	-63	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATORX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ATORX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ATORX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ATORXDie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: ATORXDie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATORX in 3 Jahren voraussichtlich hoch sein wird

Alligator Bioscience Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to kr0.46 loss, revenue downgraded

No longer forecast to breakeven

Price target decreased by 19% to kr1.90

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Recent updates

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Consensus EPS estimates upgraded to kr0.46 loss, revenue downgraded

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

High number of new directors

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

New minor risk - Share price stability

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

New minor risk - Profitability

Third quarter 2023 earnings released

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Price target decreased by 19% to kr1.90

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

High number of new directors

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021)

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Vice Chairman of the Board recently bought kr152k worth of stock

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Consensus forecasts updated

Chief Executive Officer recently bought kr51k worth of stock

Price target decreased to kr2.80

Less than half of directors are independent

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Consensus revenue estimates increase by 255%

Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022

Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer

Alligator Bioscience Announces Optimize-1 Trial Update

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: kr0.43 loss per share (vs kr0.43 loss in 3Q 2020)

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Consensus revenue estimates increase to kr5.00m

Alligator Bioscience AB (Publ) Initiates A Phase II Trial with Mitazalimab, and Drug Candidate Ator-1017 Is Soon to Follow

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Independent Director Kenth Petersson has left the company

Independent Director Kirsten Drejer has left the company

Independent Director Jonas Sjögren has left the company

Independent Director Ulrika Danielsson has left the company

Independent Chairman Peter Benson has left the company

Alligator Bioscience Presents Positive Phase I Data At ASCO for Its 4-1BB Agonist Drug Candidate ATOR-1017

Independent Director recently bought kr1.1m worth of stock